|
1.
|
|
11 p, 299.2 KB |
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes : A prospective study of HIV-positive individuals
/
Cain, Lauren E. (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ;
Caniglia, Ellen C. (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ;
Phillips, Andrew (University College London) ;
Olson, Ashley ;
Muga, Roberto (Institut Germans Trias i Pujol) ;
Pérez Hoyos, Santiago ;
Abgrall, Sophie ;
Costagliola, Dominique ;
Rubio, Rafael ;
Jarrín, Inma ;
Bucher, Heiner ;
Fehr, Jan ;
van Sighem, Ard ;
Reiss, Peter ;
Dabis, François ;
Vandenhende, Marie-Anne ;
Logan, Roger ;
Robins, James ;
Sterne, Jonathan A C ;
Justice, Amy ;
Tate, Janet ;
Touloumi, Giota ;
Paparizos, Vasilis ;
Esteve, Anna ;
Casabona-Barbarà, Jordi ;
Seng, Rémonie ;
Meyer, Laurence ;
Jose, Sophie ;
Sabin, Caroline A ;
Hernán, Miguel A ;
HIV CAUSAL Collaboration ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Objective: To compare regimens consisting of either ritonavir-boosted atazanavir or efavirenz and a nucleoside reverse transcriptase inhibitor (NRTI) backbone with respect to clinical, immunologic, and virologic outcomes. [...]
2016 -  10.1097/MD.0000000000005133
Medicine, Vol. 95 Núm. 41 (2016) , art. e5133
|
|
|
2.
|
|
9 p, 319.8 KB |
Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death
/
Olson, Ashley D. (Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom) ;
Walker, A. Sarah (Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom) ;
Suthar, Amitabh B. (South African Centre for Epidemiological Modelling and Analysis, University of Stellenbosch, South Africa) ;
Sabin, Caroline A. (Department of Infection and Population Health, University College London (UCL), London, United Kingdom) ;
Bucher, Heiner (University Hospital Basel (Basilea, Suïssa)) ;
Jarrín, Inmaculada (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Moreno, Santiago (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Pérez-Hoyos, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Porter, Kholoud (Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom) ;
Ford, Deborah (Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom) ;
Universitat Autònoma de Barcelona
Supplemental Digital Content is Available in the Text. Viremia copy-years (VCY), a time-updated measure of cumulative HIV exposure, predicts AIDS/death; although its utility in deciding when to start combination antiretroviral therapy (cART) remains unclear. [...]
2016 - 10.1097/QAI.0000000000001029
Journal of acquired immune deficiency syndromes (1999), Vol. 73 (august 2016) , p. 100-108
|
|
|
3.
|
|
8 p, 283.7 KB |
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries : A Prospective Observational Study
/
Caniglia, Ellen C. (Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA) ;
Sabin, Caroline A. (University College London, London, United Kingdom) ;
Robins, James M. (Department of Biostatistics, Harvard T.H. Chan School of Public Health) ;
Logan, Roger (Department of Epidemiology, Harvard T.H. Chan School of Public Health) ;
Cain, Lauren E. (Department of Epidemiology, Harvard T.H. Chan School of Public Health) ;
Abgrall, Sophie (Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Antoine Béclère, Service de Médecine Interne) ;
Mugavero, Michael J. (University of Alabama at Birmingham) ;
Hernandez-Diaz, Sonia (Department of Epidemiology, Harvard T.H. Chan School of Public Health) ;
Meyer, Laurence (Université Paris Sud, INSERM CESP U1018, and AP-HP, Hopital de Bicêtre, Service de Santé Publique) ;
Seng, Remonie (Université Paris Sud, INSERM CESP U1018, and AP-HP, Hopital de Bicêtre, Service de Santé Publique) ;
Drozd, Daniel R. (Division of Allergy and Infectious Diseases, School of Medicine, University of Washington) ;
Seage, George R. (Department of Epidemiology, Harvard T.H. Chan School of Public Health) ;
Bonnet, Fabrice (Bordeaux University, ISPED, INSERM U897 CHU de Bordeaux) ;
Dabis, Francois (INSERM U897, Centre Inserm Epidémiologie et Biostatistique, Université de Bordeaux, and Department of Internal Medicine, Bordeaux University Hospital) ;
Moore, Richard R. (School of Medicine, Johns Hopkins University, Baltimore, MD) ;
Reiss, Peter (Stichting HIV Monitoring, Amsterdam, Netherlands; Academic Medical Center, Department of Global Health and Division of Infectious Diseases, University of Amsterdam, and Amsterdam Institute for Global Health and Development) ;
van Sighem, Ard (Stichting HIV Monitoring, Amsterdam, Netherlands) ;
Mathews, William C. (Internal Medicine, Johns Hopkins University) ;
Del Amo, Julia (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Moreno, Santiago (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Deeks, Steven G. (Positive Health Program, San Francisco General Hospital) ;
Muga, Roberto (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Boswell, Stephen L. (Fenway Health) ;
Ferrer, Elena (Institut d'Investigació Biomèdica de Bellvitge) ;
Eron, Joseph J. (Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill) ;
Napravnik, Sonia (Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill) ;
Jose, Sophie (University College London) ;
Phillips, Andrew (University College London, London, United Kingdom) ;
Olson, Ashley (Medical Research Council Clinical Trials Unit, University College London) ;
Justice, Amy C. (VA Connecticut Healthcare System) ;
Tate, Janet P. (VA Connecticut Healthcare System) ;
Bucher, Heiner (University Hospital Basel (Basilea, Suïssa)) ;
Egger, Matthias (University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland) ;
Touloumi, Giota (Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School) ;
Sterne, Jonathan A. (School of Social and Community Medicine, University of Bristol) ;
Costagliola, Dominique (Institute Pierre Louis d'Épidémiologie et de Santé Publique) ;
Saag, Michael (Department of Medicine, University of Alabama at Birmingham) ;
Hernán, Miguel A. (Department of Medicine, University of Alabama at Birmingham) ;
Universitat Autònoma de Barcelona
Supplemental Digital Content is Available in the Text. To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring strategies in HIV-positive individuals on antiretroviral therapy (ART). [...]
2016 - 10.1097/QAI.0000000000000956
Journal of acquired immune deficiency syndromes (1999), Vol. 72 (may 2016) , p. 214-221
|
|
|
4.
|
|
11 p, 679.0 KB |
Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?
/
Jarrin, Inma (Instituto de Salud Carlos III) ;
Pantazis, Nikos (Athens University Medical School, Athens, Greece) ;
Dalmau, Judith (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Phillips, Andrew N. (Research Department of Infection and Population Health) ;
Olson, Ashley (Medical Research Council Clinical Trials Unit, University College London, London, UK) ;
Mussini, Cristina (Institute of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy) ;
Boufassa, Faroudy (Univ Paris-Sud, Le Kremlim Bicetre) ;
Costagliola, Dominique (INSERM, Paris, France) ;
Porter, Kholoud (Medical Research Council Clinical Trials Unit, University College London, London, UK) ;
Blanco, Julià (Universitat de Vic - Universitat Central de Catalunya) ;
Del Amo, Julia (Instituto de Salud Carlos III) ;
Martínez Picado, Francisco Javier (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
This article compares trends in CD4 + T-cell recovery and proportions achieving optimal restoration (≥500 cells/μl) after viral suppression following combination antiretroviral therapy (cART) initiation between rapid and nonrapid progressors. [...]
2015 - 10.1097/QAD.0000000000000805
AIDS, Vol. 29 (october 2015) , p. 2323-2333
|
|
|
5.
|
|
7 p, 215.9 KB |
Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype
/
Olson, Ashley D. (University College London. Medical Research Council Clinical Trials Unit (United Kingdom)) ;
Guiguet, Marguerite (Université Pierre et Marie Curie (France)) ;
Zangerle, Robert (Innsbruck Medical University (Austria)) ;
Gill, John (University of Calgary (Canada)) ;
Pérez-Hoyos, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Lodi, Sara (Instituto de Salud Carlos III) ;
Ghosn, Jade (CHU Bicêtre. Service de Médecine Interne et Maladies Infectieuses (France)) ;
Dorrucci, Maria (Istituto Superiore di Sanità (Italy)) ;
Johnson, Anne (University College London. Institute of Epidemiology and Health Care (United Kingdom)) ;
Sannes, Mette (Ulleval University Hospital (Norway)) ;
Moreno, Santiago (Hospital Universitario Ramón y Cajal (Madrid)) ;
Porter, Kholoud (University College London. Medical Research Council Clinical Trials Unit (United Kingdom)) ;
Universitat Autònoma de Barcelona
Supplemental Digital Content is Available in the Text. Rapid CD4 cell loss represents an HIV phenotype used to identify causal variants of accelerated disease progression. The optimal rate and threshold for identifying this extreme phenotype in recently infected individuals is unclear. [...]
2014 - 10.1097/QAI.0000000000000240
Journal of acquired immune deficiency syndromes (1999), Vol. 67, Issue 1 (September 2014) , p. 15-21
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
